The present findings indicate that TAA treatment increased mitochondrial dysfunction and ROS production in the hepatocytes of Dnmt3b-deficient mice, leading to the exacerbation of hepatitis. The gene discussed is DNMT3B; the disease is hepatitis A virus infection.